JPRN-UMIN000023621已完成2 期
A phase II study on the feasibility and efficacy of preoperative chemoradiotherapy with S-1 for locally advanced rectal cancer - A phase II study on the feasibility and efficacy of preoperative chemoradiotherapy with S-1 for locally advanced rectal cancer
Department of Surgery Kindai University Faculty of Medicine0 个研究点目标入组 42 人开始时间: 2016年8月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •# Distant metastases # Cerebrovascular disease (CVD) with paralytic symptoms or prior CVD within one year. # Symptomatic or actively treated cardiac disorders. Or prior cardiac disorder within one year. # Cancerous fluid on diagnostic imaging. # Prior chemotherapy or pelvic irradiation for malignancy. # Other cancer diagnosis within the past 5 years (including colorectal cancer). # Interstitial pneumonia or fibroid lung. # Uncontrolled diabetes mellitus. # Uncontrolled hypertension # Ileus (cases with diverting stoma are eligible). # Uncontrolled diarrhea. # Pregnant, nursing or no intention to contraception. # Those considered inappropriate for participation in this trial.
研究者
相似试验
招募中
2 期
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin*s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHL10025320lymphomaNL-OMON36830HOVO60
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation - HOVON 80 NHrelapsed B cell lymphomaMedDRA version: 8.1Level: LLTClassification code 10029547Term: Non-Hodgkin's lymphomaEUCTR2006-002141-37-NLHOVON foundation35
进行中（未招募）
不适用
Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.Aggressive B-cell NHLMedDRA version: 14.1Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-007083-28-NLHOVON foundation60
招募中
2 期
A phase II study to evaluate the effectiveness of S-1 + Cetuximab for patients with advanced/recurrent colon cancer who cannot undergo intensive therapyadvanced/recurrent colon cancer patients with RAS wild-type tumors who cannot undergo intensive therapyJPRN-UMIN000018484HO HOKKAIDO CANCER CENTER Division of Gastroenterology57
进行中（未招募）
不适用
A Pilot Phase II Study for the evaluation of efficacy and tolerability of Gammaidroxybutyrate (ALCOVER) administered by oral route as add on treatmant in patients affected by DYT 11 Myoclonic Dystonia. - NDEUCTR2006-001039-23-ITISTITUTO NEUROLOGICO CARLO BESTA